Di-He Gong1,2, Yi-Yu Chen3, Ding Ma3, Hai-Yan Chen4, Ke-Feng Ding4, Ke-Da Yu3. 1. Department of Thyroid and Breast surgery, Affiliated Cixi Hospital, Wenzhou Medical University, Cixi 315300, China. 2. Department of Breast Surgery, Ningbo Hangzhou Bay Hospital, Ningbo 315336, China. 3. Department of Breast Surgery, Shanghai Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai 200032, China. 4. Department of Surgical Oncology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.
Abstract
BACKGROUND: The expression of CCL28 and its relationship with clinical outcomes remain unclear in the setting of heterogeneous breast cancer. The purpose of the current study was to identify the expression characteristics of chemokine CCL28 in breast cancer, with a focus on its prognostic relevance to different subtypes. METHODS: First, we investigated the expression of CCL28 in 150 breast cancer patients immunohistochemically and assessed the impact of CCL28 on relapse-free survival (RFS) in the whole cohort and different clinical subtypes [defined by hormone receptor (HR), and HER-2 status] by univariate and multivariate analysis. Furthermore, the other two cohorts comprised of 863 patients from the Cancer Genome Atlas (TCGA) database and 1,764 patients from the Kaplan-Meier plotter database, respectively, were chosen to validate the prognostic values of CCL28 in breast cancer. RESULTS: Those with positive CCL28 expression had improved RFS in luminal-like (HR positive, any HER-2 status) subtype (P=0.052) but had impaired RFS in triple-negative cases (P=0.019), after adjustment with tumor size and lymph node status. Consistently, multivariate analysis in the TCGA cohort revealed improved disease-free survival (DFS) among patients with high expression of CCL28 in luminal-like subtype (P=0.043) and decreased DFS in patients expressing high CCL28 in triple-negative cases (P=0.010). The subsequent analysis of the Kaplan-Meier plotter cohort also demonstrated that CCL28 was a favorable prognostic factor for luminal-like cases [luminal A (P<0.001) and luminal B (P=0.031)], but a poor prognostic indicator for the patients with triple-negative phenotype (P<0.001). CONCLUSIONS: CCL28 was a favorable prognostic factor for luminal-like cases and detrimental for triple-negative subtype, indicating that the same chemokine may play different or even opposite roles in the recurrence and metastasis of different molecular subtypes of breast cancer.
BACKGROUND: The expression of CCL28 and its relationship with clinical outcomes remain unclear in the setting of heterogeneous breast cancer. The purpose of the current study was to identify the expression characteristics of chemokine CCL28 in breast cancer, with a focus on its prognostic relevance to different subtypes. METHODS: First, we investigated the expression of CCL28 in 150 breast cancer patients immunohistochemically and assessed the impact of CCL28 on relapse-free survival (RFS) in the whole cohort and different clinical subtypes [defined by hormone receptor (HR), and HER-2 status] by univariate and multivariate analysis. Furthermore, the other two cohorts comprised of 863 patients from the Cancer Genome Atlas (TCGA) database and 1,764 patients from the Kaplan-Meier plotter database, respectively, were chosen to validate the prognostic values of CCL28 in breast cancer. RESULTS: Those with positive CCL28 expression had improved RFS in luminal-like (HR positive, any HER-2 status) subtype (P=0.052) but had impaired RFS in triple-negative cases (P=0.019), after adjustment with tumor size and lymph node status. Consistently, multivariate analysis in the TCGA cohort revealed improved disease-free survival (DFS) among patients with high expression of CCL28 in luminal-like subtype (P=0.043) and decreased DFS in patients expressing high CCL28 in triple-negative cases (P=0.010). The subsequent analysis of the Kaplan-Meier plotter cohort also demonstrated that CCL28 was a favorable prognostic factor for luminal-like cases [luminal A (P<0.001) and luminal B (P=0.031)], but a poor prognostic indicator for the patients with triple-negative phenotype (P<0.001). CONCLUSIONS: CCL28 was a favorable prognostic factor for luminal-like cases and detrimental for triple-negative subtype, indicating that the same chemokine may play different or even opposite roles in the recurrence and metastasis of different molecular subtypes of breast cancer.
Entities:
Keywords:
CCL28; breast neoplasms; subtype; survival analysis
Authors: J Pan; E J Kunkel; U Gosslar; N Lazarus; P Langdon; K Broadwell; M A Vierra; M C Genovese; E C Butcher; D Soler Journal: J Immunol Date: 2000-09-15 Impact factor: 5.422
Authors: W Wang; H Soto; E R Oldham; M E Buchanan; B Homey; D Catron; N Jenkins; N G Copeland; D J Gilbert; N Nguyen; J Abrams; D Kershenovich; K Smith; T McClanahan; A P Vicari; A Zlotnik Journal: J Biol Chem Date: 2000-07-21 Impact factor: 5.157
Authors: Li Hao; Chunhui Zhang; Yuhua Qiu; Liang Wang; Yunbao Luo; Min Jin; Yi Zhang; Taylor B Guo; Kouji Matsushima; Yanyun Zhang Journal: Cancer Lett Date: 2007-02-16 Impact factor: 8.679